Viemed Healthcare (VMD) Research & Development (2019 - 2026)

Viemed Healthcare (VMD) has reported Research & Development for 8 consecutive years, with $504000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 40.5% year-over-year to $504000.0; the trailing twelve-month figure through Jun 2026 stood at $2.5 million (down 23.35% YoY), and the FY2025 full-year result was $3.0 million, down 1.66% from the prior year.
• Research & Development declined to $504000.0 in Q2 2026 per VMD's latest filing, from $579000.0 in the prior quarter.
• Across five years, Research & Development topped out at $847000.0 in Q2 2025 and bottomed at $504000.0 in Q2 2026.
• Historically, Research & Development has averaged $702555.6 across 5 years, with a median of $736000.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Research & Development soared 86.43% in 2022, then slumped 40.5% in 2026.
• Over 5 years, Research & Development stood at $722000.0 in 2022, then declined by 9.83% to $651000.0 in 2023, then advanced by 23.35% to $803000.0 in 2024, then declined by 25.53% to $598000.0 in 2025, then dropped by 15.72% to $504000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $504000.0, $579000.0, and $598000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.